Sign up USA
Proactive Investors - Run By Investors For Investors

Baxter buys Sweden's Gambro for $4 bln

Baxter buys Sweden's Gambro for $4 bln

Drug and medical device maker Baxter International (NYSE:BAX) said Tuesday it plans to buy privately-held Swedish company Gambro for about $2.76 billion to broaden its dialysis product portfolio.

Baxter will pay for the deal with a combination of debt and cash. It expects the acquisition to close in the first half of next year. In total, the deal is worth about $4 billion, including debt.

Gambro makes dialysis products for patients with acute or chronic kidney disease, and Baxter said it had sales of about $1.6 billion last year.

Baxter has considered doing a deal with Gambro for years. Gambro is considerably smaller than Baxter, which has a market value of some $36 billion and had sales last year of $13.9 billion. The company also had more than $3 billion of cash as of September.

Baxter said dialysis treatment rates are rising by more than 5 per cent annually, partly due to growing rates of diabetes and high blood pressure. More than 2 million people globally are on some form of dialysis.

Dialysis involves removing blood from a patient, running it through a machine that cleans out impurities and then returning it to the patient's body. Baxter's medical device division makes products for kidney dialysis and intravenous administration sets to deliver medicines and fluids to patients.

Baxter also has a bioscience division that makes vaccines and high-tech treatments for hemophilia and other bleeding disorders, burns and shock, immune deficiencies and other blood-related conditions.

Baxter makes medical devices, pharmaceuticals and biotechnology products, focusing on areas including hemophilia, immune disorders and infectious diseases. 

It divides its operations between a bioscience division, which generated just under half of company sales last year, and a medical-products division, which produced the rest.



Register here to be notified of future BAX Company articles
View full BAX profile

Baxter International Timeline

Newswire
August 25 2011

Related Articles

Stem Cells
March 30 2017
WideCells is aiming to be a major supporting player through its development of a stem cell storage business and, having only listed in London last July, its newsflow so far looks to be pointing the way
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Microbes
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use